EA201690782A1 - Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты - Google Patents

Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты

Info

Publication number
EA201690782A1
EA201690782A1 EA201690782A EA201690782A EA201690782A1 EA 201690782 A1 EA201690782 A1 EA 201690782A1 EA 201690782 A EA201690782 A EA 201690782A EA 201690782 A EA201690782 A EA 201690782A EA 201690782 A1 EA201690782 A1 EA 201690782A1
Authority
EA
Eurasian Patent Office
Prior art keywords
endosomolytic
delivery system
optimized
vivo
nucleicic
Prior art date
Application number
EA201690782A
Other languages
English (en)
Other versions
EA032867B1 (ru
EA032867B9 (ru
Inventor
Дзиань-Шен Сунь
Мари Дютреи
Мария Канз
Original Assignee
Дна Терапьютикс
Энститю Кюри
Сантр Насьональ Де Ля Решерш Сьентифик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дна Терапьютикс, Энститю Кюри, Сантр Насьональ Де Ля Решерш Сьентифик filed Critical Дна Терапьютикс
Publication of EA201690782A1 publication Critical patent/EA201690782A1/ru
Publication of EA032867B1 publication Critical patent/EA032867B1/ru
Publication of EA032867B9 publication Critical patent/EA032867B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение имеет отношение к оптимизированной с помощью эндосомолитических средств системе доставки in vivo нуклеиновой кислоты, представляющей терапевтический интерес, конъюгированной с молекулами, способствующими эндоцитозу, в частности для использования при лечении рака.
EA201690782A 2010-06-22 2011-06-21 Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты EA032867B9 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10166936 2010-06-22

Publications (3)

Publication Number Publication Date
EA201690782A1 true EA201690782A1 (ru) 2016-08-31
EA032867B1 EA032867B1 (ru) 2019-07-31
EA032867B9 EA032867B9 (ru) 2020-01-22

Family

ID=42727428

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201300039A EA023927B1 (ru) 2010-06-22 2011-06-21 ОПТИМИЗИРОВАННАЯ С ПОМОЩЬЮ ЭНДОСОМОЛИТИЧЕСКИХ СРЕДСТВ СИСТЕМА ДОСТАВКИ in vivo КОНЪЮГАТОВ НУКЛЕИНОВОЙ КИСЛОТЫ
EA201690782A EA032867B9 (ru) 2010-06-22 2011-06-21 Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201300039A EA023927B1 (ru) 2010-06-22 2011-06-21 ОПТИМИЗИРОВАННАЯ С ПОМОЩЬЮ ЭНДОСОМОЛИТИЧЕСКИХ СРЕДСТВ СИСТЕМА ДОСТАВКИ in vivo КОНЪЮГАТОВ НУКЛЕИНОВОЙ КИСЛОТЫ

Country Status (20)

Country Link
US (5) US9205099B2 (ru)
EP (4) EP3135301B1 (ru)
JP (1) JP5860874B2 (ru)
CN (2) CN104788523B (ru)
AU (1) AU2011269041B2 (ru)
CA (1) CA2802463C (ru)
CY (1) CY1120560T1 (ru)
DK (2) DK3372248T3 (ru)
EA (2) EA023927B1 (ru)
ES (2) ES2674412T3 (ru)
HR (1) HRP20180934T1 (ru)
HU (1) HUE037926T2 (ru)
IL (2) IL223467A (ru)
LT (1) LT3135301T (ru)
PL (1) PL3135301T3 (ru)
PT (1) PT3135301T (ru)
RS (1) RS57439B1 (ru)
SI (1) SI3135301T1 (ru)
TR (1) TR201807294T4 (ru)
WO (1) WO2011161075A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3135301T1 (en) * 2010-06-22 2018-08-31 Onxeo OPTIMIZED SYSTEM OF DELIVERY AND VIVO WITH ENDOSOMOLITIC MEANS FOR KONJUGATE NUCLEIC ACIDS
EP2527440A1 (en) * 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
CN103550783A (zh) * 2013-04-27 2014-02-05 中国人民解放军军事医学科学院放射与辐射医学研究所 一种核酸类药物靶向递送系统及其制备方法
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
US20210052631A1 (en) * 2015-09-25 2021-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10821128B2 (en) * 2016-03-01 2020-11-03 Onxeo Treatment of cancer by systemic administration of Dbait molecules
WO2017186882A1 (en) 2016-04-29 2017-11-02 Onxeo A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
CN117919431A (zh) 2016-12-01 2024-04-26 国立大学法人埼玉大学 药物递送系统用胞吞作用增强剂及其制备方法
EP3570814B1 (en) 2017-01-19 2023-11-29 Universiteit Gent Molecular adjuvants for enhanced cytosolic delivery of active agents
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018175445A1 (en) * 2017-03-20 2018-09-27 Northwestern University Poly(lactic-co-glycolic acid) (plga) spherical nucleic acids
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
US20200407720A1 (en) * 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US20210379096A1 (en) * 2018-11-01 2021-12-09 Alpha Tau Medical Ltd. Intratumoral Alpha-Emitter Radiation and Activation of Cytoplasmatic Sensors for Intracellular Pathogen
EP3898974A1 (en) * 2018-12-21 2021-10-27 Onxeo New conjugated nucleic acid molecules and their uses
MA55219A (fr) * 2019-03-06 2022-01-12 Generation Bio Co Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7759291A (en) * 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5843643A (en) * 1992-02-21 1998-12-01 Ratner; Paul L. Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
AU691306B2 (en) 1994-06-17 1998-05-14 F. Hoffmann-La Roche Ag N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
JP2002514892A (ja) * 1995-06-08 2002-05-21 コブラ セラピューティクス リミテッド 遺伝子治療における合成ウイルス様粒子の使用
AUPN741696A0 (en) 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
KR100615117B1 (ko) * 1997-09-15 2006-08-22 제네틱 이뮤너티, 엘엘씨. 피부의 항원제시 세포에 유전자를 전달하는 방법
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
DE10310196A1 (de) 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
EP1526177A1 (en) * 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality
US7476729B2 (en) * 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
US20070293449A1 (en) 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
EP1944369A1 (en) 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
WO2009063998A1 (ja) 2007-11-14 2009-05-22 Ribomic Inc. 疎水性物質付加核酸及びその使用
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2365796A4 (en) 2008-11-07 2015-04-29 Childrens Hosp Medical Center FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS
TW201021852A (en) 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable fusogenic lipids for nucleic acids delivery systems
SI3135301T1 (en) * 2010-06-22 2018-08-31 Onxeo OPTIMIZED SYSTEM OF DELIVERY AND VIVO WITH ENDOSOMOLITIC MEANS FOR KONJUGATE NUCLEIC ACIDS
EP2527440A1 (en) * 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia

Also Published As

Publication number Publication date
EP2585113A1 (en) 2013-05-01
JP5860874B2 (ja) 2016-02-16
DK3135301T3 (en) 2018-06-25
EP3372248B1 (en) 2020-03-11
US10765758B2 (en) 2020-09-08
US20190314511A1 (en) 2019-10-17
ES2784793T3 (es) 2020-09-30
US20130131155A1 (en) 2013-05-23
SI3135301T1 (en) 2018-08-31
HUE037926T2 (hu) 2018-09-28
EA032867B1 (ru) 2019-07-31
US9687557B2 (en) 2017-06-27
US20170298089A1 (en) 2017-10-19
US10363317B2 (en) 2019-07-30
IL223467A (en) 2017-09-28
CN104788523B (zh) 2017-09-08
EP3372248A1 (en) 2018-09-12
IL252241A0 (en) 2017-08-31
HRP20180934T1 (hr) 2018-10-05
CA2802463C (en) 2019-02-26
EA201300039A1 (ru) 2013-05-30
AU2011269041B2 (en) 2015-05-07
CA2802463A1 (en) 2011-12-29
US9205099B2 (en) 2015-12-08
CN103025356A (zh) 2013-04-03
TR201807294T4 (tr) 2018-06-21
EA032867B9 (ru) 2020-01-22
RS57439B1 (sr) 2018-09-28
ES2674412T3 (es) 2018-06-29
CN103025356B (zh) 2015-02-18
EA023927B1 (ru) 2016-07-29
JP2013534521A (ja) 2013-09-05
AU2011269041A2 (en) 2013-07-11
CY1120560T1 (el) 2019-07-10
EP3135301A1 (en) 2017-03-01
PL3135301T3 (pl) 2018-11-30
US20160046662A1 (en) 2016-02-18
WO2011161075A1 (en) 2011-12-29
PT3135301T (pt) 2018-07-16
EP3135301B1 (en) 2018-05-02
AU2011269041A1 (en) 2013-01-31
LT3135301T (lt) 2018-07-10
US9428538B2 (en) 2016-08-30
DK3372248T3 (da) 2020-04-06
EP3689381A1 (en) 2020-08-05
CN104788523A (zh) 2015-07-22
US20160339107A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
EA201690782A1 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
AU2020201329C1 (en) Conjugates for treating diseases caused by PSMA expressing cells
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
PH12015501953A1 (en) Substituted nucleotide analogs
MX361218B (es) Análogos de spliceostatina.
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
EA201290727A1 (ru) Пирролбензодиазепины и их конъюгаты
UA110370C2 (en) Conjugates of amatoxin with improved linkages
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
MX2018011836A (es) Conjugados de anticuerpo farmaco anti-cd70.
NZ710729A (en) Amatoxin derivatives
MX349035B (es) Portadores para el suministro mejorado de farmaco.
MY173826A (en) Oligonucleotide conjugates
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EP2303337A4 (en) MEDICAMENT-LIGAND SMALL MOLECULE CONJUGATES FOR TARGETED CANCER TREATMENT
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
MX2019007057A (es) Composiciones de adenovirus.
EA201890598A2 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
IL228943A0 (en) Cancer treatment using a combination of DNA molecules that mimic double-strand breaks with hyperthermia
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM